Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : IPSEN Research and Development, BEAUFOUR IPSEN PHARMA

Femme et Homme Max 99 ans
IPSEN Research and Development, BEAUFOUR IPSEN PHARMA MAJ Il y a 4 ans

Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg administered every 28 days on tumour progression free survival in patients with non functioning entero-pancreatic endocrine tumour The main objective is to assess the effect of lanreotide Autogel 120 mg administered every 28 days compared to placebo, on progression-free survival in patients with well or moderately differentiated ...

Pays Aucun
Organes Aucun
Spécialités Aucune

unknown

Plus d'informations